Overview: The purpose of this study is to examine the safety tolerability and antiviral efficacy of GS-7977 and RBV in treatment naive and experienced subjects with chronic genotype 2 or 3 HCV infection who are coinfected with HIV-1. A total of 10 subjects will be enrolled at Mount Sinai and 100 subjects at all sites. The total time to complete all study visits is approximately 40 weeks include 28 day (4 week) screening period 12 week treatment period and up to 24 week post-treatment period.
Overview: The purpose of this open-label Phase 3 study is to learn more about the safety and effects of the combination of telaprevir peginterferon alfa-2a (Peg-IFN) and ribavirin (RBV) in subjects with chronic hepatitis C (HCV) and HIV. Subjects with genotype 1 HCV and HIV will be eligible to participate in the research study. The study will include 2 groups - Group A will include subjects with HCV and HIV who have either not received treatment for HCV or have previously relapsed after treatment for HCV. Group B will include subjects who have previously received treatment for HCV but did not respond or had only partial response to treatment. Participation in the study will last 124 weeks with 10 subjects enrolled at Mount Sinai.
Overview: Ponatinib will be used to control the patient's chronic myelogenous leukemia (CML) while searching for the best available donor for an allogeneic stem cell transplant. The patient is running out of treatment options after having received 3 tyrosine kinase inhibitors that target the mutation that causes CML and is still showing evidence of the mutation.